Orphan Drug Designation from FDA
Seite 1 von 1 Neuester Beitrag: 29.11.17 16:18 | ||||
| Eröffnet am: | 29.11.16 12:03 | von: apfelrücken | Anzahl Beiträge: | 3 |
| Neuester Beitrag: | 29.11.17 16:18 | von: wow-stocks | Leser gesamt: | 6.170 |
| Forum: | Börse | Leser heute: | 1 | |
| Bewertet mit: |  | |||
ab hier nocheinmal 50 % hoch ?
Den Einstieg gestern leider verpasst...
Gestern mit hohem Volumen mit + 149 %
https://finance.yahoo.com/quote/pzrx?ltr=1
SEATTLE, Nov. 28, 2016 /PRNewswire/ -- PhaseRx, Inc. (PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced that its lead candidate, PRX-OTC, which is being developed for the treatment of ornithine transcarbamylase deficiency (OTCD), has received orphan drug designation by the U.S. Food and Drug Administration (FDA).
http://finance.yahoo.com/news/...phan-drug-designation-133000462.html
Den Einstieg gestern leider verpasst...
Gestern mit hohem Volumen mit + 149 %
https://finance.yahoo.com/quote/pzrx?ltr=1
SEATTLE, Nov. 28, 2016 /PRNewswire/ -- PhaseRx, Inc. (PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced that its lead candidate, PRX-OTC, which is being developed for the treatment of ornithine transcarbamylase deficiency (OTCD), has received orphan drug designation by the U.S. Food and Drug Administration (FDA).
http://finance.yahoo.com/news/...phan-drug-designation-133000462.html
Hochriskant aber auch Vervielfachungspotential. Story stimmt. Sollte ein Pharmakonzern die Human Trials finanzieren und oder die Plattform lizensieren wird es sehr schnell auf 5 - 10 Dollar gehen. Denke das ist noch ein total unbekannter Biotech Wert. Die ersten Aktien wurden mit 5 Dollar ausgegeben.
We are engaged in discussions with a number of biopharmaceutical companies regarding partnership opportunities focused on our product pipeline, the use of our Hybrid mRNA Technology for the delivery of potential partners’ mRNAs and the use of Hybrid mRNA Technology for in vivo gene editing.
https://phaserx.com/partnering/
We are engaged in discussions with a number of biopharmaceutical companies regarding partnership opportunities focused on our product pipeline, the use of our Hybrid mRNA Technology for the delivery of potential partners’ mRNAs and the use of Hybrid mRNA Technology for in vivo gene editing.
https://phaserx.com/partnering/
